Usefulness of fecal calprotectin by monoclonal antibody testing in adult Japanese with inflammatory bowel diseases: a prospective multicenter study = Usefulness of fecal calprotectin by monoclonal antibody testing in adult Japanese with inflammatory bowel diseases: a prospective multicenter study

다국어 초록 (Multilingual Abstract)

Background/Aims: Noninvasive objective monitoring is advantageous for optimizing treatment strategies in patients inflammatory bowel disease (IBD). Fecal calprotectin (FCP) is superior to traditional biomarkers in terms of assessing the activity in patients with IBD. However, there are the differences among several FCP assays in the dynamics of FCP. In this prospective multicenter trial, we investigated the usefulness of FCP measurements in adult Japanese patients with IBD by reliable enzyme immunoassay using a monoclonal antibody. Methods: We assessed the relationship between FCP levels and disease or endoscopic activity in patients with ulcerative colitis (UC, n=64) or Crohn’s disease (CD, n=46) compared with healthy controls (HCs, n=64). Results: FCP levels in UC patients strongly correlated with the Disease Activity Index (r_s=0.676, P<0.0001) and Mayo endoscopic subscore (MES; r_s=0.677, P<0.0001). FCP levels were significantly higher even in patients with inactive UC or CD compared with HCs (P=0.0068, P<0.0001). The optimal cutoff value between MES 1 and 2 exhibited higher sensitivity (94.1%). FCP levels were significantly higher in active UC patients than in inactive patients (P<0.001), except those with proctitis. The Crohn’s Disease Activity Index tended to correlate with the FCP level (rs=0.283, P=0.0565). Conclusions: Our testing method using a monoclonal antibody for FCP was well-validated and differentiated IBD patients from HCs. FCP may be a useful biomarker for objective assessment of disease activity in adult Japanese IBD patients, especially those with UC. (Intest Res 2018;16:554-562)

참고문헌 (Reference)

• 1 Tibble JA, "Use of surrogate markers of inflammation and Rome criteria to distinguish organic from nonorganic intestinal disease" 123 : 450-460, 2002
• 2 Feuerstein JD, "Ulcerative colitis: epidemiology, diagnosis, and management" 89 : 1553-1563, 2014
• 3 Silverberg MS, "Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology" 19 (19): 5A-36A, 2005
• 4 Henderson P, "The diagnostic accuracy of fecal calprotectin during the investigation of suspected pediatric inflammatory bowel disease: a systematic review and meta-analysis" 109 : 637-645, 2014
• 5 Hanai H, "Relationship between fecal calprotectin, intestinal inflammation, and peripheral blood neutrophils in patients with active ulcerative colitis" 49 : 1438-1443, 2004
• 6 Ma C, "Noninvasive fecal immunochemical testing and fecal calprotectin predict mucosal healing in inflammatory bowel disease: a prospective cohort study" 23 : 1643-1649, 2017
• 7 Selinger CP, "Mortality from inflammatory bowel diseases" 18 : 1566-1572, 2012
• 8 Burri E, "Monoclonal antibody testing for fecal calprotectin is superior to polyclonal testing of fecal calprotectin and lactoferrin to identify organic intestinal disease in patients with abdominal discomfort" 416 : 41-47, 2013
• 9 Enck P, "Irritable bowel syndrome" 2 : 16014-, 2016
• 10 Yang SK, "Identification of loci at 1q21 and 16q23 that affect susceptibility to inflammatory bowel disease in Koreans" 151 : 1096-1099, 2016
• 11 Inokuchi T, "Fecal immunochemical test versus fecal calprotectin for prediction of mucosal healing in Crohn's disease" 22 : 1078-1085, 2016
• 12 Ikhtaire S, "Fecal calprotectin: its scope and utility in the management of inflammatory bowel disease" 51 : 434-446, 2016
• 13 Schoepfer AM, "Fecal calprotectin more accurately reflects endoscopic activity of ulcerative colitis than the Lichtiger Index, C-reactive protein, platelets, hemoglobin, and blood leukocytes" 19 : 332-341, 2013
• 14 Kawashima K, "Fecal calprotectin level correlated with both endoscopic severity and disease extent in ulcerative colitis" 16 : 47-, 2016
• 15 Aomatsu T, "Fecal calprotectin is a useful marker for disease activity in pediatric patients with inflammatory bowel disease" 56 : 2372-2377, 2011
• 16 Yamaguchi S, "Fecal calprotectin is a clinically relevant biomarker of mucosal healing in patients with quiescent ulcerative colitis" 31 : 93-98, 2016
• 17 Manceau H, "Fecal calprotectin in inflammatory bowel diseases: update and perspectives" 55 : 474-483, 2017
• 18 Kopylov U, "Fecal calprotectin for the prediction of small-bowel Crohn's disease by capsule endoscopy: a systematic review and meta-analysis" 28 : 1137-1144, 2016
• 19 Lin WC, "Fecal calprotectin correlated with endoscopic remission for Asian inflammatory bowel disease patients" 21 : 13566-13573, 2015
• 20 Li F, "Fecal calprotectin concentrations in healthy children aged 1-18 months" 10 : e0119574-, 2015
• 21 Taghvaei T, "Fecal calprotectin and ulcerative colitis endoscopic activity index as indicators of mucosal healing in ulcerative colitis" 10 : 321-328, 2015
• 22 Lopez RN, "Fecal biomarkers in inflammatory bowel disease" 32 : 577-582, 2017
• 23 Aomatsu T, "Faecal chitinase 3-like-1: a novel biomarker of disease activity in paediatric inflammatory bowel disease" 34 : 941-948, 2011
• 24 van Rheenen PF, "Faecal calprotectin for screening of patients with suspected inflammatory bowel disease: diagnostic meta-analysis" 341 : c3369-, 2010
• 25 Ueno F, "Evidence-based clinical practice guidelines for Crohn's disease, integrated with formal consensus of experts in Japan" 48 : 31-72, 2013
• 26 Cosnes J, "Epidemiology and natural history of inflammatory bowel diseases" 140 : 1785-1794, 2011
• 27 Ket SN, "Endoscopic disease activity in inflammatory bowel disease" 17 : 50-, 2015
• 28 Menees S, "Does colonoscopy cause increased ulcerative colitis symptoms?" 13 : 12-18, 2007
• 29 Dabritz J, "Diagnostic utility of faecal biomarkers in patients with irritable bowel syndrome" 20 : 363-375, 2014
• 30 Fukunaga S, "Detection of calprotectin in inflammatory bowel disease: fecal and serum levels and immunohistochemical localization" 41 : 107-118, 2018
• 31 Walsh AJ, "Current best practice for disease activity assessment in IBD" 13 : 567-579, 2016
• 32 Loftus EV Jr, "Crohn's disease: why the disparity in mortality?" 55 : 447-449, 2006
• 33 Torres J, "Crohn's disease" 389 : 1741-1755, 2017
• 34 Bressler B, "Clinicians' guide to the use of fecal calprotectin to identify and monitor disease activity in inflammatory bowel disease" 29 : 369-372, 2015
• 35 Amcoff K, "Clinical implications of assay specific differences in f-calprotectin when monitoring inflammatory bowel disease activity over time" 52 : 344-350, 2017
• 36 Scaioli E, "Clinical application of faecal calprotectin in ulcerative colitis patients" 27 : 1418-1424, 2015
• 37 Mosli MH, "C-reactive protein, fecal calprotectin, and stool lactoferrin for detection of endoscopic activity in symptomatic inflammatory bowel disease patients: a systematic review and meta-analysis" 110 : 802-819, 2015
• 38 Panes J, "Advances in use of endoscopy, radiology, and biomarkers to monitor inflammatory bowel diseases" 152 : 362-373, 2017
• 39 Lobaton T, "A new rapid test for fecal calprotectin predicts endoscopic remission and postoperative recurrence in Crohn's disease" 7 : e641-e651, 2013
• 40 Lobaton T, "A new rapid quantitative test for fecal calprotectin predicts endoscopic activity in ulcerative colitis" 19 : 1034-1042, 2013
• 41 Sutherland LR, "5-Aminosalicylic acid enema in the treatment of distal ulcerative colitis, proctosigmoiditis, and proctitis" 92 : 1894-1898, 1987